nextpoint therapeutics nextpoint therapeutics

We will also retain your Personal Data as necessary to comply with our legal obligations, resolve disputes, and enforce our agreements. Detlev is a serial entrepreneur and an experienced biopharma executive who brings deep knowledge of oncology and immuno-oncology to his role. In Dr. Gandhis next role as Vice President of Immuno-Oncology Development at Eli Lilly, she led the development of novel immuno-oncology agents across cancer types before returning to Dana-Farber in 2020, where she most recently served as the Director of the Center for Cancer Therapeutic Innovation a cross-malignancy novel therapeutics hub. We are thrilled to support NextPoint, an exciting addition to our oncology portfolio, as it works to redefine the treatment landscape of immuno-oncology.. Related Persons. To assist you in using the Website, we have created (i) these Terms of Use (the Terms), and (ii) aPrivacy Notice. Freemans and Zangs independent discovery and characterization of the HHLA2 pathway formed the basis of the NextPoint approach. NextPoints approach re-activates immune cells in tumors that are suppressed by HHLA2-driven immune evasion. Settings. Among these areas are oncology, immunology, rare diseases, vaccines, potential cures in other core areas of Sanofis business footprint, and digital health solutions. (DE), Bayer and Follow-up Questions, How to Menu, Our The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments. To analyze and improve our Services, administer our Site and Services, provide you with access to our Services, analyze and improve our information technology, monitor compliance with our Terms of Use, and enforce our Terms of Use or other legal or regulatory obligations, Geolocation Data such as physical location information that may be provided by the device you are using. a Glance, Latest be communicated, falling within Article 49(2)(a) to (d) of the Order (all such persons together A spokesperson for Boston-based NextPoint declined . Republic, Dominican Bayers leadership in agriculture provides tailored solutions Our innovative approach integrates foundational science with a defined clinical biomarker to deliver a new class of monotherapies for patients who will not benefit from PD-1/L1 inhibitors. NEXTPOINT THERAPEUTICS, INC. Company Number 7059407 Incorporation Date 17 September 2018 (over 4 years ago) Company Type Corporation Jurisdiction Delaware (US) Agent Name THE CORPORATION TRUST COMPANY Agent Address CORPORATION TRUST CENTER 1209 ORANGE ST, WILMINGTON, New Castle, DE, 19801 Directors / Officers THE CORPORATION TRUST COMPANY, agent 6. Nutrition Bar on Crop Protection Safety Standards, UN Protection, Environmental 2021 Jul 9;6(61):9792. In fiscal 2021, the Group employed around 100,000 people and had sales of 44.1 billion euros. If you want to block the use and saving of cookies from the Site on to the computers hard drive, you should take the necessary steps within your web browsers settings to block all cookies from the Site and its external serving vendors, or use the cookie control system, if available upon first visit. However, if you would like to make a request for information under the Shine The Light law, please contact us at the Contact Us section below. Our innovative approach integrates foundational science with a defined clinical biomarker to deliver a new class of monotherapies for patients who will not benefit from PD-1/L1 inhibitors. Zhao R, Chinai JM, Buhl S, et al. About. The following materials are not directed at or to be accessed by persons located in the United A browser sends cookies to a server when the browser makes a connection to the server (for example, when requesting a web page from the same domain that created the cookie). Announcements, Sustainability & Arabia, South in the United States absent registration or an applicable exemption from the registration Cancer Immunol Res. We have no control over, do not review, and are not responsible for Third-Party Sites, their content, or any goods or services available through the Third-Party Sites. any facility of a national securities exchange of the United States and the tender offer cannot be Read more about our economic, ecological and social challenges and opportunities. Leverkusen, ESG Ratings and Your computer and mobile devices when you access our Site. language options. By clicking on the I AGREE button, I confirm that I am permitted Agriculture, Growth NextPoint Therapeutics has announced an $80 million Series B funding round to move two lead precision immuno-oncology programs into the clinic. +49 2173 380. Similar to PD-L1, the tumor antigen HHLA2 is a member of the B7 receptor family, is highly expressed on certain hard-to-treat cancers, and drives avoidance of detection from the immune system. This time around, we note that NextPoint Therapeutics hired Leena Gandhi as chief medical officer. Arab Emirates, United Leaps by Bayer, a unit of Bayer AG, leads impact investments into solutions to some of todays biggest challenges in health and agriculture. Compliance Policy, Bayer Nextpoint, the industry-leader in cloud-based eDiscovery and Litigation support software, has secured $4.5 million in non-dilutive, growth capital. Bayer, Meet Find out more: www.sanofiventures.com, Kira PeikoffLeaps by Bayer1(973)791-3348kira.peikoff@bayer.com. offering or an invitation to the public in connection with any offer within the meaning of These materials do not constitute or form a part of any offer or The securities referred to herein will not be registered under the U.S. Securities Act of 1933, as Calculator, Voting Rights Looking for a job in an innovative company? available on the website of the Luxembourg Stock Exchange (www.bourse.lu). Report, More While immune checkpoint inhibitors targeting PD-1/L1 have revolutionized cancer treatments, many patients do not benefit from these medications and require novel therapeutic strategies. access to the materials is prohibited or restricted. Drs. CAMBRIDGE, Mass. Our Site may use the following technologies to implement cookies and pixels: If you do not wish to receive any interest-based advertising, you can deactivate Googles use of cookies for these purposes by going tohttps://www.google.com/settings/ads. 51373 Leverkusen He initiated newco research activities with Dr. Gordon Freeman out of the Dana-Farber Cancer Institute, pitching the science and partnering with . Alternatively, you may contact us atinfo@nextpointtx.comto opt-out of direct marketing. These materials may not be transmitted over the Website without the copyright owners permission or without a legitimate fair use justification for the transmittal. Lists Featuring This Company "La investigacin de NextPoint Therapeutics proporciona una comprensin profunda de un mecanismo novedoso, la va Hhla2, que apaga el sistema inmunitario en los tumores; nuestro objetivo es desarrollar nuevos tratamientos para pacientes con cncer", segn explica Biniszkiewicz, director ejecutivo de NextPoint Therapeutics. Reporting to the Chief Medical Officer, the Vice President will build our Translational Medicine capability, responsible for managing research activities bridging from discovery to clinical development. The financing will be used to advance NextPoint . Your computer and mobile devices when you visit our Site. The securities are only available to, and any invitation, & Teamwork, Better Education, Health, For more information. Viewing the materials you seek to access may not be lawful in certain and Life in balance, Healthy About Sanofi VenturesSanofi Ventures is the corporate venture capital arm of Sanofi. buy Leena Gandhi, MD, PhD, was named chief medical officer of NextPoint Therapeutics, a biotechnology company focused on immuno-oncology through its work on the HHLA2 pathway. on NextPoint Therapeutics Announces $80 Million Series B Financing co-led by Leaps by Bayer and Sanofi Ventures to Advance Novel Immuno-Oncology Programs, LabCentral, 238 Main Street, 5th Floor, Cambridge, MA 02142. The financing will be used to advance NextPoints two lead precision immuno-oncology programs into the clinic, both targeting the newly discovered HHLA2 pathway to activate anti-tumor immune responses. for Life, The The financing will be used to advance NextPoint . Republic of, New Dr. Zang is professor of microbiology & immunology, of medicine, . Locations, Your on prohibited or restricted. ////// Science for a better NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today that it raised $80 million in Series B financing co-led by Leaps by Bayer, the impact investment arm of Bayer AG, and Sanofi Ventures, the strategic venture capital arm for Sanofi. Development Policy, Corporate Provide sufficient information that allows us to reasonably verify you are the person about whom we collected personal information or an authorized representative. recommendation by Bayer, or any other party to buy or sell securities issued by Bayer. Board, Document Download The verifiable consumer request must: California Civil Code Section 1798.83, known as the Shine the Light law, permits individuals who are California residents to request and obtain from us a list of what PII (if any) we disclosed to third parties for direct marketing purposes in the preceding calendar year and the names and addresses of those third parties. China, United We are thrilled to support NextPoint, an exciting addition to our oncology portfolio, as it works to redefine the treatment landscape of immuno-oncology.. By clicking on the I AGREE button, I certify that I am not located in the United States, Global Product Strategy, Position We do not accept any responsibility or liability for these policies and procedures. News, Conditions of Authority, United Arab Sanofi Ventures invests in early-stage biotech and digital health companies with innovative ideas and transformative new products and technologies of strategic interest to Sanofi. Statements, Questions This announcement does not contain or constitute an offer of, Both programs of the Boston-based company use the recently . To analyze and improve our Services, administer our Site and Services, provide you with access to our Services, analyze and improve our information technology, monitor compliance with our Terms of Use, and enforce our Terms of Use or other legal or regulatory obligations. About NextPoint Therapeutics NextPoint is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 pathway. Some cookies and other technologies may serve to track Personal Data previously entered by a web user on our site. Its products and services are designed to help people and the planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. Bayer is committed to driving sustainable development and generating a positive impact with its businesses. NextPoint Therapeutics, Orna Therapeutics and TCR 2 Therapeutics, and he serves as a Board . at Team, Our Freemans and Zangs independent discovery and characterization of the HHLA2 pathway formed the basis of the NextPoint approach. jurisdiction. Career Worldwide, Data To access YOU EXPRESSLY AGREE THAT USE OF THE WEBSITE AND RELATED CONTENT IS AT YOUR SOLE RISK. Global, Bayer Angela Poppe Ries, MD, was named chief medical officer of VyncaCare, a home healthcare company for patients living with serious illness. Describe your request with sufficient detail that allows us to properly understand, evaluate, and respond to it. 50 the Bayer press portal. Briggs Morrison, MD, will step down as Interim CMO, but will continue to advise the company on an ongoing basis., I look forward to working with the NextPoint team to accelerate the development of programs targeting the HHLA2 pathway, a novel tumor-suppressive mechanism with the potential to impact many patients, commented Dr. Gandhi. Interested in finding out more?Please send your resume and cover letter to HR@nextpointtx.com. Conduct, Product Proc Natl Acad Sci U S A. Sustainable Development Goals, Position Professional skill highlights: lab facility planning and fit out, lab operations management, project management, document management (QMS), budgeting, procurement, safety program management and technical training. Bachelor of Science required, Masters of Science preferred. For more information, go to. on In the United Kingdom the following materials are only directed at (i) investment professionals Management, Bayer About Leaps by BayerLeaps by Bayer, a unit of Bayer AG, leads impact investments into solutions to some of todays biggest challenges in health and agriculture. Importantly, HHLA2 is independent of PD-L1 and is often most strongly expressed in PD-L1-negative cancers. for Prescription Medicine in Europe, Counterfeits in US precision immuno-oncology biotech NextPoint Therapeutics has raised $80 million in a Series B financing co-led by Leaps by Bayer, the impact investment arm of Germany's Bayer (BAYN: DE), and Sanofi Ventures, the strategic venture capital arm for French drugmaker Sanofi (Euronext: SAN). I am currently pursuing a M.Sc. Development, Test CS | Learn more about Anne Koehler, PhD's . Alternatively, users can deactivate cookies from third-party providers by going to the network advertising initiatives deactivation page (link:https://optout.networkadvertising.org/?c=1). Use, Privacy Copyright and Legal Notice. NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today the appointment of Leena Gandhi, MD, PhD, as Chief Medical Officer (CMO).. As CMO, Dr. Gandhi will oversee the clinical development of NextPoint's precision immuno-oncology programs that target the newly discovered HHLA2 pathway to activate anti-tumor immune responses. Position, Position NextPoint Therapeutics Raises $80M in Series B Financing | Precision Oncology News The firm plans to put the funds toward its investigational immunotherapies targeting HHLA2 on difficult-to-treat, PD-L1-negative cancers. The Bayer brand stands for trust, reliability and quality throughout the world. Our innovative approach integrates foundational. Life & Challenges, Reputation Please note, however, we cannot fully eliminate security risks associated with the storage and transmission of Personal Data. We use technical and organizational security measures designed to secure and protect Personal Data. They are all working on potentially breakthrough technologies to overcome some specific challenges such as, e.g., developing a sustainable protein supply, reducing the environmental impact of agriculture, preventing or curing cancer, and others. Investing in a stronger future - for our shareholders, and interstate or foreign commerce, or of any facility of a national securities exchange of the United Personal Information does not include publicly available information, information that is de-identified, aggregated information, or any other information outside the scope of the California Consumer Privacy Act of 2018 (CCPA). For more information, go to leaps.bayer.com. Founded by MPM Capital, NextPoint Therapeutics has assembled a team of proven drug developers to build a broad strategic pipeline of first-in-class immunotherapies based on this validated checkpoint axis, with the goal of delivering new options to people with cancer. made on the basis of the securities prospectus. These factors include those discussed in Bayers public reports which are available on the Bayer website at www.bayer.com. The support of our new investors along with the continued commitment of our existing investors and founders emphasizes our momentum and progress in defining precision immuno-oncology for new patient segments., Juergen Eckhardt, MD, Head of Leaps by Bayer, commented, Leaps by Bayer was founded to help solve ten of the worlds biggest challenges in health and agriculture, including preventing and curing cancer. The AP news staff was not involved in its creation. Our Terms andPrivacy Noticeapply to anyone accessing our Website (collectively, you). Kaiser-Wilhelm-Allee 1 Bayer and the opportunities available. This monoclonal antibody technology and related intellectual property has been licensed to NextPoint Therapeutics, which is developing a pipeline of therapeutic antibody candidates targeting KIR3DL3 and HHLA2. 10-01-2023 Print. life. Management, Code of Conduct us, How circumstances, constitute a public offering or an invitation to the public in connection with any (888) 929-NEXT 4043 N Ravenswood Ave, #317, Chicago, 60613 hello@nextpoint.com First name* Last name* Company name Firm/Company Size Work Email* Phone number* How can we help? of Self-Care, Outperforming Bayers leadership in agriculture provides tailored solutions for farmers to plant, grow and protect their harvests using less land, water and energy. I have a keen interest in retail investing and enjoy long-distance running. For purposes of this Privacy Notice, Personal Data means any information relating to an identified or identifiable natural person. Making press Our team of proven drug developers is working closely with our renowned scientific founders to launch a new world of precision immuno-oncology. Protected classification characteristics under California or federal law such as age, gender, gender identity, gender expression, health information, education, We do not generally collect this information, Commercial information, such a Services provided, your interaction with our Site and Services, To allow you access to our Services, to provide you with Services, to respond to questions you may have.